CI-CY

B | C-CH | CI-CY | D-DIF

Product #

Image

Product Name

Biochem/physiol Actions

Gene Symbol (ID)

Add to Cart
C7249 CI-1033 ≥98% (HPLC) CI-1033 is a potent, irreversible ATP binding site–directed pan-ErbB tyrosine kinase inhibitor with IC50 in the low nanomolar range for EGFR, HER2, and ErbB-4.
  
    • C3743 CI 976 >98% (HPLC), solid CI-976, a new trimethoxy fatty acid anilide, is a potent and specific inhibitor of liver and intestinal acyl coenzyme A; cholesterol acyltransferase (ACAT) in vitro. CI-976 decreased non-high density lipoprotein (HDL)-cholesterol and increased HDL-cholesterol in rats with pre-established dyslipidemia. High performance gel chromatographic separation of plasma lipoproteins also revealed that CI-976, but not CL 277,082, lowered low density lipoprotein (LDL)-cholesterol and elevated HDL-cholesterol.
    		  
    • C0621 CI−994 ≥98% (HPLC), powder CI-994 is the acetylated derivative form of the original compound Dinaline (PD 104 208). It is an oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells. It is used for combination therapy for selected tumors including non-small cell lung, pancreatic, breast, and colorectal cancers. It acts as a histone deacetylase inhibitor. CI-994 blocks cells in the G1-S phase of the cell cycle. The 16 kDa phosphoprotein is confined to the nuclear compartment. Loss of the 16-kDa nuclear phosphoprotein appears to be a direct effect of CI-994 treatment and that the inhibition of this phosphoprotein may play a critical role in the mechanism of action of CI-994.
    		  
    • C1618 Cibenzoline succinate ≥97% (NMR), solid Cibenzoline is a class IA antiarrhythmic drug. Cibenzoline (μM concentrations) blocks ATP-sensitive K channels in heart and pancreatic cells. Cibenzoline interacts with the channel pore-forming subunit of the K(ATP) channel (Kir6.2) from the cytoplasmic side. Cibenzoline also inhibits the delayed rectifier K current [I(Kr)] in sino-atrial node cells.
    		  
    • C5874 Cidofovir hydrate ≥98% (HPLC) Selective inhibitor of viral DNA synthesis through the selective inhibition of viral DNA polymerase.
    		  
    • C3974 Ciglitizone ≥99% (TLC) Selective peroxisome proliferator-activated receptor-γ (PPARγ) agonist (EC50 = 3 μM) and antihyperglycemic agent displaying activity in genetically obese C57 B1/6 ob/ob mice.
    		 human ... PPARG(5468)
    mouse ... Pparg(19016)
    • C5492 CIL-102 ≥95% (HPLC), solid CIL-102 is a tubulin polymerization inhibitor: apoptosis inducer.
    		  
    • C1493 Cilnidipine ≥98% (HPLC), powder Cilnidipine is a slow-acting Ca2+ channel blocker; antihypertensive; vasodilator; dual blocker of L-type voltage-gated Ca2+ channels in vascular smooth muscle and N-type Ca2+ channels in sympathetic nerve terminals that supply blood vessels. Cilnidipine may offer an advantage over nifedipine as the long term intake of the latter has been linked to increased risk of myocardial infarction and mortality in patients with coronary artery disease. Cilnidipine lowers blood pressure, but has less effect on sympathetic activity. Unlike nifedipine, cilnidipine does not inhibit PKC.
    		  
    • C7971 Cilostamide phosphodiesterase inhibitor Selective inhibitor of PDE3 (cGMP-inhibited phosphodiesterase); IC50 = 70 ± 9 nM. This inhibitory effect increases intracellular cAMP and inhibits platelet aggregation.1
    		 human ... PDE3A(5139), PDE3B(5140), PDE5A(8654), PDE7A(5150)
    rat ... Pde2a(81743), Pde4a(25638)
    • C0737 Cilostazol >99% (HPLC), solid Phosphodiesterase III (PDE3) inhibitor
    		 human ... PDE3A(5139), PDE3B(5140)
    • C4522 Cimetidine H2 histamine receptor antagonist; I1 imidazoline receptor agonist; anti-ulcer agent. Blocks cancer metastasis by inhibiting the expression of E-selectin on the surface of endothelial cells, thus blocking tumor cell adhesion.
    		 human ... ABCB1(5243), CYP1A2(1544), CYP3A4(1576), HRH2(3274), SLC9A2(6549), SLC9A5(6553)
    mouse ... Abcb1a(18671), Abcb1b(18669)
    rat ... Slc9a1(24782), Slc9a3(24784), Slc9a5(192215)
    • C6239 Cinalukast ~98% (HPLC) Specific CysLT1 leukotriene receptor antagonist.
    		 human ... CYSLTR1(10800)
    • 27350 Cinchonidine purum, ≥98.0% (dried material, NT)   human ... CYP2D6(1565)
    • C80407 Cinchonidine 96%   human ... CYP2D6(1565)
    • 27370 Cinchonine crystallized, ≥98.0% (NT)   human ... CYP2D6(1565)
    • SML0096 Cinnabarinic Acid ≥98% (HPLC) Cinnabarinic acid is a kynurenine pathway metabolite of tryptophan, produced by the oxidation of 3-Hydroxyanthranilic acid. Cinnabarinic acid leads to loss of mitochondrial respiration and apoptosis, and has also been shown to be an mGlu4R-specific agonist.
    		  
    • C5241   Cinnamycin from Streptomyces cinnamoneus, ≥95% (HPLC) Cinnamycin is a tetracyclic polypeptide antibiotic containing 19 amino acids. The polypeptide has the unusual amino acids threo-3-methyl-lanthionine, meso-lanthionine, lysinoalanine and 3-hydroxyaspartic acid. It is produced by Streptomyces cinnamoneus and belongs to the duramycin-type l antibiotics. Lantibiotics are synthesized in the ribosome and undergo extensive post-translational modifications to attain their active antimicrobial form.1,2,3 The unique receptor for Cinnamycin, phosphatidylethanolamine (PE), is located on the inner leaflet of the plasma membrane.4,5 Cinnamycin induces transbilayer lipid movement leading to the exposure of PE to the outer leaflet of the plasma membrane.2,4, The interaction of Cinnamycin with PE provides a tool for PE monitoring.5 Cinnamycin is active against Gram-positive rods such as Bacilli, Clostyridium and Mycobacterium, causing cell wall biosynthesis stress.2
    Cinnamycin, like other lantibiotics, was also reported to inhibit phospholipase A2 (PLA2).1 It was suggested as an alternative treatment for atherosclerosis through its ability to inhibit PLA2 by binding to its substrate PE.2,5 Moreover, Cinnamycin was found to inhibit Herpes simplex virus (HSV-1) activity.6
    		 
    • SML0105 Cinnamyl-3,4-dihydroxy-α-cyanocinnamate ≥98% (HPLC) Cinnamyl-3,4-dihydroxy-α-cyanocinnamate (CDC) is a potent and direct inhibitor of 5-LO (5-Lipoxygenase) that reduces 5-LO activity in cell-free assays. CDC also inhibits 12-LO and 15-LO
    		  
    • C5270 Cinnarizine powder Ca2+ channel blocker; central and peripheral vasodilator.
    		 human ... CACNA1A(773), DRD2(1813), HRH1(3269)
    • C0330 Ciprofibrate Peroxisome proliferator-activated receptor α (PPARα) agonist
    		 human ... PPARA(5465)
    • 17850 Ciprofloxacin ≥98.0% (HPLC)   human ... CYP1A2(1544), KCNH1(3756)
    rat ... Gabra1(29705)
    • C6492 Ciproxifan hydrochloride ≥98% (HPLC), solid Ciproxifan belongs to a novel chemical series of histamine H3-receptor antagonists. In vitro, it behaved as a competitive antagonist at the H3 autoreceptor controlling 3H histamine release from synaptosomes and displayed similar Ki values (0.5-1.9 nM) at the H3 receptor controlling the electrically-induced contraction of guinea pig ileum or at the brain H3 receptor labeled with 125I-iodoproxyfan. Ciproxifan appears to be an orally bioavailable, extremely potent and selective H3-receptor antagonist whose vigilance- and attention-promoting effects are promising for therapeutic applications in aging disorders.
    		  
    • C6848 Ciproxifan maleate ≥98% (HPLC), solid Potent, selective H3 histamine receptor antagonist.
    		  
    • SML0229   CIQ ≥98% (HPLC) CIQ is positive allosteric modulator of NR2C/NR2D subunit containing NMDA receptors. CIQ increases channel opening frequency of recombinant NR2Cor NR2D containing receptors by two-fold (EC50 = 2.7 and 2.8 μM, respectively), with no effect on NR2A or NR2B subtypes. The compound does not alter the EC50 values for glutamate or glycine on channel opening.
    		  
    • C223 Cirazoline hydrochloride solid Selective α1-adrenoceptor agonist; non-selective imidazoline binding site ligand
    		 human ... ADRA1A(148), ADRA1B(147), ADRA1D(146)
    • C4740 Cisapride monohydrate ≥98% (HPLC), solid 5-HT4 serotonin receptor agonist.
    		  
    • C7861 Citalopram hydrobromide solid Potent and selective serotonin uptake inhibitor (Ki = 5.4 nM); antidepressant
    		 human ... HTR1A(3350), HTR1B(3351), HTR1D(3352), HTR1E(3354), HTR1F(3355), HTR2A(3356), HTR2B(3357), HTR2C(3358), HTR3A(3359), HTR3B(9177), HTR3C(170572), HTR3D(200909), HTR3E(285242), HTR4(3360), HTR5A(3361), HTR5B(645694), HTR6(3362), HTR7(3363)
    • C6240 CITCO ≥98% (HPLC), solid CITCO is a constitutive androstane receptor (CAR) agonist; nuclear receptor NR113 agonist.
    		  
    • W230316 Citral natural, ≥95%, FCC, FG   human ... CYP1A2(1544)
    • C83007 Citral 95%   human ... CYP1A2(1544)
    • W230308 Citral mixture of cis and trans, ≥96%, FG   human ... CYP1A2(1544)
    • 38730   Citrate standard for IC 1000 mg/L, analytical standard   human ... SRC(6714)
    • C2404 Citric acid anhydrous, cell culture tested, plant cell culture tested   human ... SRC(6714)
    • 251275 Citric acid ACS reagent, ≥99.5%   human ... SRC(6714)
    • C83155 Citric acid 99%   human ... SRC(6714)
    • 46933 Citric acid analytical standard   human ... SRC(6714)
    • 27487 Citric acid BioUltra, anhydrous, ≥99.5% (T)   human ... SRC(6714)
    • 27109 Citric acid meets analytical specification of Ph. Eur., BP, USP, E330, anhydrous, 99.5-100.5% (based on anhydrous substance)   human ... SRC(6714)
    • W230618 Citric acid ≥99.5%, FCC, FG   human ... SRC(6714)
    • C7629 L-Citrulline ≥98% (TLC) Intermediate in the production of nitric oxide from L-arginine by NO synthetase.
    		  
    • SML0187 CJ-13610 ≥98% (HPLC) CJ-13,610 is a potent inhbititor of 5-lipoxygenase (5-LO) activity (IC50 = 70 nM).
    		  
    • SML0080 CJB 090 dihydrochloride hydrate ≥98% (HPLC) CJB 090 is a Dopamine D3 receptor partial agonist. CJB 090 was found to attenuate the discriminative stimulus (DS) effects of cocaine while showing no cocaine-like effects when tested alone, and has also been shown to reduce methamphetamine self-administration.
    		  
    • C7499 CK-548 ≥98% (HPLC) CK-548 inhibits the activity of actin-related protein (Arp)2/3 complex by inserting into the hydrophobic core of Arp3 and altering its conformation: inhibits
    		  
    • C7374 CK-636 ≥98% (HPLC) CK-636 binds between Arp2 and Arp3, where it appears to block movement of Arp2 and Arp3 into their active conformation. CK-636 inserts into the hydrophobic core of Arp3 and alters its conformation. Both classes of compounds inhibit formation of actin filament comet tails by Listeria and podosomes by monocytes.
    		  
    • C0742 CKI-7 dihydrochloride ≥98% (HPLC), solid CKI-7 is a CK1 inhibitor; also inhibits SGK, S6K1 and MSK1. CKI-7 inhibits SGK as potently as CK1. IC50 = 6 μM.
    		  
    • C5976 CL 316,243 hydrate ≥98% (HPLC), powder CL 316,243 is a β3 adrenoceptor agonist; anti-obesity agent.
    		 human ... ADRB3(155)
    • L7035 clasto-Lactacystin β-lactone Cell-permeable and irreversible proteasome inhibitor. Lactacystin acts as a precursor for clasto-lactacystin β-lactone.
    		  
    • C5423 Clenbuterol hydrochloride ≥95% β2-adrenoceptor agonist, bronchodilator.
    		  
    • 34190 Clethodim PESTANAL®, analytical standard   rat ... Acaca(60581)
    • C8414 Clobazam Anxiolytic; ligand for the GABAA receptor benzodiazepine modulatory site.
    		  
    • C209 Clobenpropit dihydrobromide solid Selective H3 histamine receptor antagonist that crosses the blood-brain barrier.
    		  
    • C8037 Clobetasol propionate analytical standard   rat ... Nr3c1(24413)
    • C7495 Clofarabine ≥98% (HPLC) Clofarabine is a purine nucleoside antimetabolite. Clofarabine is toxic to nondividing lymphocytes and monocytes.
    		  
    • C8895 Clofazimine    
    • C6643 Clofibrate liquid Peroxisome proliferator-activated receptor-α (PPARα) agonist. Antihyperlipoproteinemic believed to act by inhibiting cholesterol biosynthesis.
    		 human ... PPARA(5465)
    mouse ... Ppara(19013)
    • 25895 Clofibrate ≥98.0% (GC)    
    • C2365 Clofilium tosylate >97%, solid K+ channel blocker; cardiac depressant; anti-arrhythmic
    		  
    • C1983 Cloflubicyne ≥95% (NMR), solid    
    • C7291 Clomipramine hydrochloride ≥98% (HPLC), powder Tricyclic antidepressant; inhibits serotonin and norepinephrine transporters.
    		 human ... HTR1A(3350), HTR1B(3351), HTR1D(3352), HTR1E(3354), HTR1F(3355), HTR2A(3356), HTR2B(3357), HTR2C(3358), HTR3A(3359), HTR3B(9177), HTR3C(170572), HTR3D(200909), HTR3E(285242), HTR4(3360), HTR5A(3361), HTR5B(645694), HTR6(3362), HTR7(3363)
    • C1277 Clonazepam powder Anticonvulsant; ligand for the GABAA receptor benzodiazepine modulatory site.
    		 rat ... Tspo(24230)
    • C7897 Clonidine hydrochloride solid α2-adrenoceptor agonist; I1 imidazoline binding site ligand.
    		 human ... ADRA2A(150), ADRA2B(151), ADRA2C(152)
    • 27545 Clonidine hydrochloride ≥98.0% (TLC)    
    • C0614 (±) Clopidogrel hydrogensulfate ≥98% (HPLC), powder Inhibits ADP-induced platelet aggregation; anti-thrombotic drug.
    		  
    • C6116 (+/-)-Cloprostenol sodium salt hydrate ≥98% (HPLC), powder Cloprostenol is a potent FP prostanoid receptor agonist. It is 2- to 3-fold more potent than fluprostenol but less selective. Cloprostenol is similar in potency to PGF2α at EP and TP prostanoid receptors. It is used for the treatment of infertility in sows and gilts.
    		  
    • C3977   Clostridium difficile Toxin A lyophilized powder Clostridium difficile Toxin A and B, cation-dependent UDP-glucose glucosyltransferases, are cellular toxins that inactivate Rho (and Rho family small GTPases) through monoglucosylation of these family members. Effects of this monoglucosylation include disregulation of the actin cytoskeleton, cell rounding, cytotoxicity, and altered cellular signaling. Rho proteins are monoglucosylated by Toxin A and B using UDP-glucose as a cosubstrate. Rho, Rac and Cdc42 are included in the Rho subfamilies targeted by both toxins. Low molecular mass GTP-binding proteins that are not modified by Toxin A and B include Ras, Rab, Arf, or Ran subfamilies as well as heterotrimeric G proteins.
    		  
    • C4102   Clostridium difficile Toxin B lyophilized powder Clostridium difficile Toxin A and B, cation-dependent UDP-glucose glucosyltransferases, are cellular toxins that inactivate Rho (and Rho family small GTPases) through monoglucosylation of these family members. Effects of this monoglucosylation include disregulation of the actin cytoskeleton, cell rounding, cytotoxicity, and altered cellular signaling. Rho proteins are monoglucosylated by Toxin A and B using UDP-glucose as a cosubstrate. Rho, Rac and Cdc42 are included in the Rho subfamilies targeted by both toxins. Low molecular mass GTP-binding proteins that are not modified by Toxin A and B include Ras, Rab, Arf, or Ran subfamilies as well as heterotrimeric G proteins.
    Toxin B is 100-1,000-fold more cytotoxic than toxin A in inducing rounding-up of cells and destruction of the actin cytoskeleton.
    		  
    • C6019 Clotrimazole Specific inhibitor of Ca2+-activated K+ channels. Antifungal azole. Antifungal mode of action: Inhibits cytochrome P450-dependent 14α-demethylase, which is critical to ergosterol biosynthesis. The accumulated 14α-methylated sterols change the membrane structure of sensitive fungi, altering cell membrane permeability.
    		 human ... ABCB1(5243), CYP17A1(1586), CYP3A4(1576)
    mouse ... Abcb1a(18671), Abcb1b(18669)
    • C6305 Clozapine Atypical antipsychotic compound. Selective antagonist for D4-dopamine receptor. Antagonist at 5-HT2A, 5-HT2C, 5-HT3, 5-HT6, and 5-HT7 serotonin receptors.
    		 human ... ADRA1A(148), ADRA2A(150), ADRA2C(152), CHRM1(1128), DRD2(1813), DRD3(1814), DRD4(1815), HRH1(3269), HRH4(59340), HTR2A(3356), HTR2C(3358), HTR3A(3359), HTR3B(9177), HTR3C(170572), HTR3D(200909), HTR3E(285242), HTR6(3362), HTR7(3363), KCNH1(3756), KCNH2(3757), UGT1A4(54657)
    rat ... Adra1a(29412), Adra2a(25083), Adrb1(24925), Chrm1(25229), Drd1a(24316), Drd2(24318), Drd3(29238), Drd4(25432), Hrh1(24448), Htr1a(24473), Htr1b(25075), Htr2a(29595), Htr2b(29581), Htr2c(25187), Htr3a(79246), Htr7(65032), Slc6a4(25553)
    • C0832 Clozapine N-oxide 5-HT2 serotonin receptor antagonist; major metabolite of clopazine that can be monitored by HPLC.
    		  
    • C127 CNQX ≥98% (HPLC), solid Potent, competitive AMPA/kainate glutamate receptor antagonist.
    		 rat ... Gria1(50592), Grik1(29559), Grik2(54257), Grik4(24406), Grin2a(24409)
    • C239 CNQX disodium salt hydrate ≥98% (HPLC), solid Potent, competitive AMPA/kainate receptor antagonist.
    		 human ... ADORA1(134), ADORA2A(135), ADORA2B(136), ADORA3(140), GRIA1(2890), GRIA2(2891), GRIA3(2892), GRIA4(2893)
    • C4238 CNS-1102 >98% (HPLC), solid Noncompetitive NMDA glutamate receptor antagonist.
    		  
    • C6903   α-Cobratoxin from Naja naja kaouthia Long chain post-synaptic neurotoxin that binds nicotinic receptors and blocks cholinergic neurotransmission at the neuromuscular junction; binding is irreversible.
    		  
    • C8912 Cocaine free base Inhibits the dopamine, norepinephrine, and serotonin transporters with Kis of about 300 nM, 900 nM, and 400 nM, respectively. Unlike amphetamines, it has no effect on catecholamine release.
    		 human ... DRD3(1814), KCNH1(3756), KCNH2(3757), SCN10A(6336), SCN11A(11280), SCN5A(6331), SLC6A2(6530), SLC6A3(6531), SLC6A4(6532)
    mouse ... Slc6a2(20538)
    rat ... Chrm1(25229), Slc6a3(24898), Slc6a4(25553)
    • C5776 Cocaine hydrochloride Inhibits the dopamine, norepinephrine, and serotonin transporters with Kis of about 300 nM, 900 nM, and 400 nM, respectively. Unlike amphetamines, it has no effect on catecholamine release.
    		  
    • 610089 Cocaine solution 1 mg/mL in acetonitrile, analytical standard, for drug analysis   human ... KCNH1(3756), KCNH2(3757), SLC6A2(6530), SLC6A3(6531), SLC6A4(6532)
    mouse ... Slc6a2(20538)
    rat ... Chrm1(25229), Slc6a3(24898), Slc6a4(25553)
    • C5901 Codeine Weak narcotic analgesic, perhaps due to conversion to morphine, with minimal hypnotic properties; potent antitussive
    		 human ... CYP2D6(1565), OPRD1(4985), OPRK1(4986), OPRM1(4988)
    rat ... Cyp2d1(266684), Cyp2d2(25053), Cyp2d3(24303), Cyp2d4v1(171522)
    • C1653 Codeine solution analytical standard, for drug analysis, 1.0 mg/mL±5% in methanol   human ... CYP2D6(1565), OPRD1(4985), OPRK1(4986), OPRM1(4988)
    rat ... Cyp2d1(266684), Cyp2d2(25053), Cyp2d3(24303), Cyp2d4v1(171522)
    • C3230 Coelenterazine h solid 10 times higher luminescence intensity than native coelenterazine.
    		  
    • C2855   Coelenterazine cp solid 15 times higher luminescence and faster response time than native coelenterazine (Prod. No. C2230).
    		  
    • C3105 Coelenterazine fcp solid 135 times higher luminescence intensity than native coelenterazine
    		  
    • C3355 Coelenterazine hcp solid 190 times higher luminescence intensity with a faster response time than native coelenterazine (Prod. No. C2230).
    		  
    • C2230 Coelenterazine, native solid Luminophore of the aequorin complex which is oxidized by oxygen to illuminate at 465 nm when Ca2+ binds to the complex; used to measure Ca2+ concentration in cells with high sensitivity and large dynamic range.
    		  
    • C8081 Coenzyme Q2 ≥90% Acts as an electron carrier and antioxidant in humans
    		  
    • C2470 Coenzyme Q4 ≥90% Increases the fluorescence polarization of perylene incorporated into ubiquinone-depleted mitochondrial and bilayer vesicles prepared from mitochondrial phospholipids
    		  
    • C9538 Coenzyme Q10 ≥98% (HPLC) Endogenous cellular antioxidant; essential component of the electron transfer chain.
    		  
    • C3915 Colchicine BioReagent, plant cell culture tested, ≥95% (HPLC) Colchicine is an inhibitor of microtubule polymerization which blocks chromosome segregation during meiosis. Consequently, Colchicine is used to induce polyploidy (tetraploid) in plant cells.
    		 human ... ABCB1(5243), CYP3A4(1576)
    mouse ... Abcb1a(18671), Abcb1b(18669)
    • C9754 Colchicine ≥95% (HPLC), powder Antimitotic agent that disrupts microtubules by binding to tubulin and preventing its polymerization. Stimulates the intrinsic GTPase activity of tubulin. Induces apoptosis in several normal and tumor cell lines and activates the JNK/SAPK signaling pathway.
    		 human ... ABCB1(5243), CYP3A4(1576)
    mouse ... Abcb1a(18671), Abcb1b(18669)
    • 27650 Colchicine ≥96.0% (HPLC)    
    • C4361   Collagen Type I−FITC Conjugate from bovine skin ~1 mg/mL, solution Substrate for assaying mammalian collagenase activity in cell culture.
    		cow ... COL1A1(282187), COL1A2(282188)
    human ... MMP1 (includes EG:4312)(4312)
    mouse ... MMP1 (includes EG:4312)(83995)
    rat ... MMP1 (includes EG:4312)(300339)
    • C7744 Combretastatin A4 ≥98% (HPLC), powder Combretastatin A4 is a vascular disrupting agent (VDA) that targets tumor vasculature to inhibit angiogenesis. It inhibits tubulin polymerization at the colchicine-binding site of beta-tubulin. It has antitumor activity by inhibiting AKT function in human gastric cells. The inhibited AKT activation causes decreased cell proliferation, cell cycle arrest, and reduced in vitro migration/invasiveness and in vivo metastatic ability. Combretastatin A4 is a natural stilbenoid phenol.
    		  
    • C2313   Compound 48/80 Promotes release of histamine. Inhibits calmodulin and activates G proteins.
    		  
    • C1733 [Glu3,4,7,10,14]-Conantokin G >90% (HPLC) Highly conserved polypeptide NMDA glutamate receptor antagonist; acts through a potent noncompetitive inhibition of polyamine responses; approximately 7-fold more potent than spermine
    		  
    • C9705 Concanamycin A ≥70% (HPLC) Cytotoxic. Inhibits acidification of organelles and perforin-mediated cytotoxicity.
    		  
    • C2272   Concanavalin A from Canavalia ensiformis (Jack bean) biotin conjugate, Type IV, lyophilized powder Con A is not blood group specific but has an affinity for terminal α-D-mannosyl and α-D-glucosyl residues. Ca2+ and Mn2+ ions are required for activity. Con A dissociates into dimers at pH 5.6 or below. Between pH 5.8 and pH 7.0, Con A exists as a tetramer; above pH 7.0 higher aggregates are formed. Con A exhibits mitogenic activity which is dependent on its degree of aggregation. Succinylation results in an active dimeric form which remains a dimer above pH 5.6.
    		  
    • L7647   Concanavalin A from Canavalia ensiformis (Jack bean) Type VI, lyophilized powder Con A is not blood group specific but has an affinity for terminal α-D-mannosyl and α-D-glucosyl residues. Ca2+ and Mn2+ ions are required for activity. Con A dissociates into dimers at pH 5.6 or below. Between pH 5.8 and pH 7.0, Con A exists as a tetramer; above pH 7.0 higher aggregates are formed. Con A exhibits mitogenic activity which is dependent on its degree of aggregation. Succinylation results in an active dimeric form which remains a dimer above pH 5.6.
    		  
    • C7275   Concanavalin A from Canavalia ensiformis (Jack bean) Type V, lyophilized powder Con A is not blood group specific but has an affinity for terminal α-D-mannosyl and α-D-glucosyl residues. Ca2+ and Mn2+ ions are required for activity. Con A dissociates into dimers at pH 5.6 or below. Between pH 5.8 and pH 7.0, Con A exists as a tetramer; above pH 7.0 higher aggregates are formed. Con A exhibits mitogenic activity which is dependent on its degree of aggregation. Succinylation results in an active dimeric form which remains a dimer above pH 5.6.
    		  
    • C7642   Concanavalin A from Canavalia ensiformis (Jack bean) FITC conjugate, Type IV, lyophilized powder Con A is not blood group specific but has an affinity for terminal α-D-mannosyl and α-D-glucosyl residues. Ca2+ and Mn2+ ions are required for activity. Con A dissociates into dimers at pH 5.6 or below. Between pH 5.8 and pH 7.0, Con A exists as a tetramer; above pH 7.0 higher aggregates are formed. Con A exhibits mitogenic activity which is dependent on its degree of aggregation. Succinylation results in an active dimeric form which remains a dimer above pH 5.6.
    		  
    • C2010   Concanavalin A from Canavalia ensiformis (Jack bean) Type IV, lyophilized powder Con A is not blood group specific but has an affinity for terminal α-D-mannosyl and α-D-glucosyl residues. Ca2+ and Mn2+ ions are required for activity. Con A dissociates into dimers at pH 5.6 or below. Between pH 5.8 and pH 7.0, Con A exists as a tetramer; above pH 7.0 higher aggregates are formed. Con A exhibits mitogenic activity which is dependent on its degree of aggregation. Succinylation results in an active dimeric form which remains a dimer above pH 5.6.
    		  
    • C5275   Concanavalin A from Canavalia ensiformis (Jack bean) Type IV-S, lyophilized powder, aseptically processed, BioReagent, suitable for cell culture Con A is not blood group specific but has an affinity for terminal α-D-mannosyl and α-D-glucosyl residues. Ca2+ and Mn2+ ions are required for activity. Con A dissociates into dimers at pH 5.6 or below. Between pH 5.8 and pH 7.0, Con A exists as a tetramer; above pH 7.0 higher aggregates are formed. Con A exhibits mitogenic activity which is dependent on its degree of aggregation. Succinylation results in an active dimeric form which remains a dimer above pH 5.6.
    		  
    • C9017   Concanavalin A from Canavalia ensiformis (Jack bean) Sepharose® conjugate, buffered aqueous suspension Con A is not blood group specific but has an affinity for terminal α-D-mannosyl and α-D-glucosyl residues. Ca2+ and Mn2+ ions are required for activity. Con A dissociates into dimers at pH 5.6 or below. Between pH 5.8 and pH 7.0, Con A exists as a tetramer; above pH 7.0 higher aggregates are formed. Con A exhibits mitogenic activity which is dependent on its degree of aggregation. Succinylation results in an active dimeric form which remains a dimer above pH 5.6.
    		  
    • C0412   Concanavalin A from Canavalia ensiformis (Jack bean) Type IV-S, lyophilized powder, γ-irradiated, BioReagent, suitable for cell culture Con A is not blood group specific but has an affinity for terminal α-D-mannosyl and α-D-glucosyl residues. Ca2+ and Mn2+ ions are required for activity. Con A dissociates into dimers at pH 5.6 or below. Between pH 5.8 and pH 7.0, Con A exists as a tetramer; above pH 7.0 higher aggregates are formed. Con A exhibits mitogenic activity which is dependent on its degree of aggregation. Succinylation results in an active dimeric form which remains a dimer above pH 5.6.
    		  
    • C7555   Concanavalin A from Canavalia ensiformis (Jack bean) agarose conjugate, Type VI, saline suspension Con A is not blood group specific but has an affinity for terminal α-D-mannosyl and α-D-glucosyl residues. Ca2+ and Mn2+ ions are required for activity. Con A dissociates into dimers at pH 5.6 or below. Between pH 5.8 and pH 7.0, Con A exists as a tetramer; above pH 7.0 higher aggregates are formed. Con A exhibits mitogenic activity which is dependent on its degree of aggregation. Succinylation results in an active dimeric form which remains a dimer above pH 5.6.
    		  
    • L6397 Concanavalin A from Canavalia ensiformis (Jack bean) peroxidase conjugate, lyophilized powder Con A is not blood group specific but has an affinity for terminal α-D-mannosyl and α-D-glucosyl residues. Ca2+ and Mn2+ ions are required for activity. Con A dissociates into dimers at pH 5.6 or below. Between pH 5.8 and pH 7.0, Con A exists as a tetramer; above pH 7.0 higher aggregates are formed. Con A exhibits mitogenic activity which is dependent on its degree of aggregation. Succinylation results in an active dimeric form which remains a dimer above pH 5.6.
    		  
    • SML0095 Conessine ≥97% (HPLC) Conessine is a plant steroid alkaloid that acts as a potent and specific antagonist of histamine H3 receptors (Ki = 5.37 and 24.5 nM for human and rat receptors, respectively). Conessine is 1860-fold selective for H3 over H4 and does not bind to H1 or H2 receptors. The molecule also binds to the human α2C4 adrenergic receptor (pKi = 7.98).
    		  
    • C9915   ω-Conotoxin GVIA ≥97% (HPLC) Blocks specific voltage-dependent N-type Ca2+ channels in neurons, but not in muscle; does not bind to either the dihydropyridine or verapamil binding sites; peptide first isolated from the marine snail Conus geographus L.
    		 human ... CACNA1B(774)
    mouse ... CACNA1B(12287)
    rat ... CACNA1B(257648)
    • C1182 ω-Conotoxin MVIIA ≥95% (HPLC) Neuronal N-type Ca2+ channel blocker in mammalian and amphibian brain; blocks release of GABA and glutamate at neuronal synapses.
    		 human ... CACNA1B(774)
    mouse ... CACNA1B(12287)
    rat ... CACNA1B(257648)
    • C4188 ω-Conotoxin MVIIC ≥95% (HPLC) Inhibits Ca2+ channels resistant to ω-Conotoxin GVIA; blocks hippocampal excitatory post-synaptic potential (EPSPs) suggesting an interaction with Q-type voltage-sensitive Ca2+ channels (VSCC); originally isolated from marine snail Conus geographus.
    		  
    • C3394 Cordycepin from Cordyceps militaris Cordycepin is an adenosine analogue that is readily converted to cordycepin 5′-triphosphate; can be used for 3′-end labeling of RNA.
    		 rat ... Adora1(29290)
    • C2505 Corticosterone ≥92% Corticosterone is a glucocorticoid secreted by the adrenal cortex that activates both mineralocorticoid and glucocorticoid receptors.
    		 human ... EBP(10682), SERPINA6(866)
    rat ... Ar(24208), Nr3c1(24413)
    • 46148 Corticosterone VETRANAL™, analytical standard   human ... EBP(10682), SERPINA6(866)
    rat ... Ar(24208), Nr3c1(24413)
    • 27840 Corticosterone ≥98.5% (HPLC) Corticosterone is a glucocorticoid secreted by the adrenal cortex that activates both mineralocorticoid and glucocorticoid receptors.
    		 human ... EBP(10682), SERPINA6(866)
    rat ... Ar(24208), Nr3c1(24413)
    • C174   Corticosterone: HBC complex free flowing powder    
    • C2917   Corticotropin Releasing Factor Antagonist ≥97% (HPLC) The corticotropin releasing factor (CRF) antagonist α-helical CRF [9-41] exhibits 10-fold higher affinity for rat CRF2α receptors over human CRF2α receptors. It has been used to elucidate the role of CRF in various physiological systems. In colonic epithelium, it abolishes CRF-induced changes in ion secretion, and significantly inhibits CRF-stimulated conductance. It antagonizes the CRF-induced proinflammatory degranulation of perivascular mast cells that are activated in response to acute psychological stress and CRF secretion.
    		 human ... CRH(1392)
    mouse ... CRH(12918)
    rat ... CRH(81648)
    • C246   Corticotropin Releasing Factor Antagonist ≥97% (HPLC), powder The corticotropin releasing factor (CRF) antagonist α-helical CRF [9-41] exhibits 10-fold higher affinity for rat CRF2α receptors over human CRF2α receptors. It has been used to elucidate the role of CRF in various physiological systems. In colonic epithelium, it abolishes CRF-induced changes in ion secretion, and significantly inhibits CRF-stimulated conductance. It antagonizes the CRF-induced proinflammatory degranulation of perivascular mast cells that are activated in response to acute psychological stress and CRF secretion.
    		 human ... CRH(1392)
    mouse ... CRH(12918)
    rat ... CRH(81648)
    • C2755 Cortisone ≥98% Cortisone is a glucocorticoid; a corticosterone analog that has approximately twice the anti-inflammatory potency as corticosterone but much lower Na2+ retention potency.
    		 human ... SERPINA6(866)
    • C3130 Cortisone 21-acetate ≥99%   human ... FNTA(2339)
    • C3255 Corynanthine   human ... CYP2D6(1565)
    • C5923 (−)-Cotinine ≥98% Major metabolite of nicotine in humans.
    		 human ... CYP1A2(1544), CYP2A6(1548)
    mouse ... Cyp2a5(13087)
    • C0430 (−)-Cotinine solution drug standard, 1.0 mg/mL±5% in methanol   human ... CYP1A2(1544), CYP2A6(1548)
    mouse ... Cyp2a5(13087)
    • 124591 2-Coumaranone 97%   human ... CYP1A2(1544)
    • C4261 Coumarin ≥99% (HPLC)   rat ... Maoa(29253), Maob(25750)
    • C85603 Coumarin-3-carboxylic acid 99%   human ... PTPN1(5770)
    • W526509 Coumarin, Chinese   rat ... Maoa(29253), Maob(25750)
    • 27883 Coumestrol BioReagent, suitable for fluorescence, ≥97.5% (HPLC) Coumestrol has anti-estrogenic actions in the brain and pituitary, mediated through estrogen receptor-α.1
    		 human ... ESR1(2099), ESR2(2100)
    mouse ... Esr1(13982)
    rat ... Ar(24208)
    • 27885 Coumestrol ≥95.0% (HPLC) Coumestrol has anti-estrogenic actions in the brain and pituitary, mediated through estrogen receptor-α.1
    		 human ... ESR1(2099), ESR2(2100)
    mouse ... Esr1(13982)
    rat ... Ar(24208)
    • PZ0136 CP-100263 dihydrochloride hydrate ≥97% (HPLC) CP-100263 is an NK-1 neurokinin receptor antagonist.
    		  
    • PZ0107 CP-101537 ≥98% (HPLC) CP-101537 is a MMP inhibitor, candidate drug for myocardial infarction therapy, and antibacterial.
    		  
    • SML0053 CP-101,606 ≥98% (HPLC) Traxoprodil (CP-101,606) is a potent noncompetitive antagonist of N-methyl-D-aspartate (NMDA) receptors, selective for the NR2B subunit. It has been shown to be neuroprotective in animal models of brain injury and stroke.
    		  
    • PZ0121 CP-135807 ≥98% (HPLC) CP-135807 is a selective 5-HT1D agonist.
    		  
    • PZ0100 CP-154526 hydrochloride ≥98% (HPLC) CP-154526 is a selective, non-peptide antagonist of corticotropin releasing factor receptors (CRF1).
    		  
    • PZ0101 CP-226269 ≥98% (HPLC) CP-226269 is a D4 dopamine receptor agonist with EC50 of 32 nM.
    		  
    • PZ0115 CP-31398 dihydrochloride hydrate ≥98% (HPLC) CP-31398 dihyrochloride hydrate is a p53 stabilizer; apoptosis inducer.
    		 human ... TP53(7157)
    mouse ... TP53(22059)
    rat ... TP53(24842)
    • PZ0189 CP-316819 ≥98% (HPLC) CP-316819 is a potent glycogen phosphorylase inhibitor. (IC50 = 40 nM against human liver GPα.) Under low glucose conditions, CP-316819 facilitates glycogen utilization in the brain, prevents neuronal cell death and maintains brain electrical currents.
    		  
    • PZ0108 CP-335963 ≥98% (SDS-PAGE) CP-335963 is an aurora 2 kinase inhibitor, PDGF inhibitor, and anti-proliferative.
    		  
    • PZ0103 CP-346086 dihydrate ≥97% (HPLC) CP-346086 is microsomal triglyceride transfer protein (MTP, MTTP) inhibitor.
    		  
    • PZ0129 CP-380736 ≥98% (HPLC) CP-380736 is an inhibitor of the epidermal growth factor receptor (EGFR). EGFR is a tyrosine kinase that activates MAPK, JNK, and Akt pathways, and is an important mediator of several types of cancer, including lung cancer and glioblastoma multiforme.
    		  
    • PZ0137 CP-471474 ≥98% (HPLC) CP-471474 is a broad spectrum inhibitor of matrix metalloproteinases. CP-471474 has a low nM IC50 efficacy for MMP-2, MMP-3, MMP-9, and MMP-13. CP-471474 has low potency against MMP-1 (IC50 > 1 uM). CP-471474 prevents left ventricular remodeling after experimental myocardial infarction in mice. CP-471474 also inhibits cigarette smoke-induced lung inflammation and the progression of emphysema in guinea pig models.
    		  
    • C1112 CP-55940 >98% (HPLC), powder CP-55940 is a selective cannabinoid receptor agonist.
    		 human ... CNR1(1268), CNR2(1269)
    rat ... Cnr1(25248)
    • PZ0130 CP-64434 hydrate ≥98% (HPLC) CP-064434 is an antibiotic; anti-proliferative HDAC inhibitor.
    		  
    • PZ0124 CP-66713 ≥98% (HPLC) CP-66713 is an adenosine A2 receptor antagonist.
    		  
    • PZ0127   CP-74416 methanesulfonate hydrate ≥98% (HPLC) CP-74416 is a primary Danofloxacin metabolite. The compound belongs to a group of quinolone antibiotic. CP-74416 is an inhibitor of the bacterial DNA gyrase.
    		 
    • PZ0173 CP-775146 ≥98% (HPLC) CP-775146 is a potent and selective PPARα agonist.
    		  
    • PZ0104 CP-91149 ≥98% (HPLC) CP-91149 is a selective glycogen phosphorylase inhibitor.
    		  
    • PZ0102 CP-93129 dihydrochloride hydrate ≥98% (HPLC) CP-93129 is a potent and selective 5-HT1B agonist.
    		  
    • SML0125 CPA 1 hydrate ≥98% (HPLC) CPA 1 is a potent, selective, ATP-competitive dual inhibitor of protein kinase casein kinase 2 (CK2) and proviral insertion Moloney virus kinases (Pim kinases). CPA 1 is selective for CK2 and Pim kinases (Pim-1, Pim-2, and Pim-3) when evaluated against a panel of 112 protein kinases.
    		  
    • C3118 CPNQ ≥98% (HPLC), solid Misfolded proteins accumulate in many neurodegenerative diseases, including huntingtin in Huntington′s disease and alpha-synuclein in Parkinson′s disease. The disease-causing proteins can take various conformations and are prone to aggregate and form larger cytoplasmic or nuclear inclusions. CPNQ (B2) was identified as a compound that promotes inclusion formation in cellular models of both Huntington′s disease and Parkinson′s disease. Despite the aggregate-forming specifics the compound prevents huntingtin-mediated proteasome dysfunction and reduces alpha-synuclein-mediated toxicity. These results demonstrate that compounds that increase inclusion formation may actually lessen cellular pathology in both Huntington′s and Parkinson′s diseases, suggesting a therapeutic approach for neurodegenerative diseases caused by protein misfolding. The ability of B2 to prevent toxicity, despite increasing inclusions, suggests that inclusions are beneficial rather than toxic, which will be further explored as the molecular target and mechanism. CPNQ (B2) is a desirable tool for both Huntington′s and Parkinson′s research.
    		 
    • C104 (±)-CPP solid Potent and selective NMDA glutamate receptor antagonist; anticonvulsant.
    		 human ... GRIN1(2902), GRIN2A(2903), GRIN2B(2904), GRIN2C(2905), GRIN2D(2906), GRINA(2907)
    rat ... Grin2a(24409)
    • C9873 CPTH2 ≥98% (HPLC), powder CPTH2 is a histone acetyltransferase (HAT) inhibitor modulating the Gcn5 network. Histone Acetyltransferase (HAT) inhibitor modulating Gcn5 network. Histone acetyltransferases (HATs) act as transcriptional coactivators. Histone acetylation plays an important role in regulating the chromatin structure and is tightly regulated by two classes of enzyme, histone acetyltransferases (HAT) and histone deacetylases (HDAC). Deregulated HAT and HDAC activity plays a role in the development of a range of cancers. Consequently, inhibitors of these enzymes have potential as anticancer agents.
    		  
    • C1055 Cromakalim Causes vasodilation by activation of potassium channels.
    		 rat ... Kcna1(24520), Kcnj1(24521), Kcnj5(29713), Kcnj8(25472)
    • C0399 Cromolyn sodium salt ≥95% Cromolyn blocks the release of histamine and other pro-inflammatory mediators from mast cells.
    		  
    • C6235 Crosstide ≥97% (HPLC), lyophilized powder Akt/PKBβ substrate.
    		 human ... AKT1(207)
    mouse ... AKT1(11651)
    rat ... AKT1(24185)
    • C7124 Cryptolepine hydrate ≥98% (HPLC) Cryptolepine hydrate is a cytoxic, anti-cancer, antimalarial agent
    		  
    • C5624 Cryptotanshinone ≥98% (HPLC) Cryptotanshinone is a quinoid diterpene isolated from the root of the Asian medicinal plant, Salvia miotiorrhiza bunge. Recently it was discovered that the compound is a potent STAT3 inhibitor. Cryptotanshinone rapidly inhibited STAT3 Tyr705 phosphorylation through a JAK2-independent mechanism. Cryptotanshinone selectively inhibits STAT3-activated cell lines through binding to monomer STAT3, subsequently blocking the dimerization and inhibiting STAT3 transcriptional regulatory activity. Previously, it was reported that the compound counteracts inflammation through the inhibition of cyclooxygenase II activity and endothelin-1 expression. In traditional oriental medicine dried roots of Salvia Miltiorrhiza Bunge (Danshen) have commonly been used for the treatment of circulatory disorders, liver disease, coronary heart disease, hepatitis, and chronic renal failure.
    		  
    • C0644 Crystal Ponceau 6R   human ... PTPN1(5770), PTPRF(5792)
    • C6499   CTB ≥98% (HPLC) CTPB was a first known small molecular activator of histone acetyltransferase p300. CTB is a simplified analog of CTPB with comparable or higher activity. The compound activates the histone acetyltransferase (HAT) activity of p300/EP300/E1A binding protein.
    		  
    • SML0068 CTP Inhibitor ≥98% (HPLC) CTP Inhibitor is an inhibitor of mitochondrial citrate transport protein, was the first purely competitive inhibitor to be discovered and is more potent than BTC.
    		  
    • C4493 Cucurbitacin I hydrate ≥97% (HPLC), solid Cucurbitacin I (JSI-124) is a novel selective inhibitor of the janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway with anti-proliferative and anti-tumor properties.
    		  
    • C87800 4-Cumylphenol 99%   rat ... Ar(24208)
    • C7727 Curcumin ≥94% (curcuminoid content), ≥80% (Curcumin) A natural phenolic compound. Potent anti-tumor agent having anti-inflammatory and anti-oxidant properties. Curcumin has been cited as a potential chemopreventive agent, in addition to its chemotherapeutic activity.1 Induces apoptosis in cancer cells and inhibits phorbol ester-induced protein kinase C (PKC) activity. Reported to inhibit production of inflammatory cytokines by peripheral blood monocytes and alveolar macrophages. Potent inhibitor of EGFR tyrosine kinase and IκB kinase. Inhibits inducible nitric oxide synthase (iNOS), cycloxygenase and lipoxygenase. Easily penetrates into the cytoplasm of cells, accumulating in membranous structures such as plasma membrane, endoplasmic reticulum and nuclear envelope.
    		 human ... APP(351), CYP1A2(1544)
    • C1386 Curcumin from Curcuma longa (Turmeric), powder A natural phenolic compound. Potent anti-tumor agent having anti-inflammatory and anti-oxidant properties. Curcumin has been cited as a potential chemopreventive agent, in addition to its chemotherapeutic activity.1 Induces apoptosis in cancer cells and inhibits phorbol ester-induced protein kinase C (PKC) activity. Reported to inhibit production of inflammatory cytokines by peripheral blood monocytes and alveolar macrophages. Potent inhibitor of EGFR tyrosine kinase and IκB kinase. Inhibits inducible nitric oxide synthase (iNOS), cycloxygenase and lipoxygenase. Easily penetrates into the cytoplasm of cells, accumulating in membranous structures such as plasma membrane, endoplasmic reticulum and nuclear envelope.
    		 human ... APP(351), CYP1A2(1544)
    • C7821   Curdlan from Alcaligenes faecalis Curdlan is a (1,3)-β-glucan. It is a pathogen-associated molecular-pattern (PAMP) recognized by the receptor dectin-1. Activation of dectin-1, together with TLR2/TLR6, promotes signaling resulting in the production of pro-inflammatory cytokines, thus inducing inflammation.1
    		  
    • C7238 CV-3988 hydrate ≥98% (HPLC), powder Competitive PAF receptor antagonist. Inhibits PAF-induced human platelet aggregation (3-30 μM) and bronchoconstriction in the guinea pig.
    		 human ... PTAFR(5724)
    • C271 CX546 ≥98% (HPLC), solid Positive AMPA glutamate receptor modulator.
    		 human ... GRIA1(2890), GRIA2(2891), GRIA3(2892), GRIA4(2893)
    • UC455 3-Cyano-7-ethoxycoumarin ≥97% (HPLC) Fluorescent probe useful in microsomal dealkylase studies. Typical drug-drug interactions resulting from enzyme inhibition.
    		  
    • C2612 3-Cyano-7-ethoxycoumarin ≥90% (at 254 nm, HPLC) Fluorescent probe useful in microsomal dealkylase studies. Typical drug-drug interactions resulting from enzyme inhibition.
    		  
    • C2020 α-Cyano-4-hydroxycinnamic acid ≥98% (TLC), powder Specific inhibitor of monocarboxylic acid transport, including lactate and pyruvate transport.1,2,3 Also reported to block β-cell apical anion exchange (IC50 of 2.4 mM).4
    		  
    • C8982 α-Cyano-4-hydroxycinnamic acid suitable for MALDI-TOF MS    
    • 39468 α-Cyano-4-hydroxycinnamic acid matrix substance for MALDI-MS, Ultra pure    
    • 70990 α-Cyano-4-hydroxycinnamic acid matrix substance for MALDI-MS, ≥99.0% (HPLC)    
    • 28480 α-Cyano-4-hydroxycinnamic acid purum, ≥99.0% (HPLC)    
    • 476870 α-Cyano-4-hydroxycinnamic acid 99%    
    • 145505 α-Cyano-4-hydroxycinnamic acid 97%    
    • UC454 3-Cyano-7-methoxycoumarin Fluorescent CYP1A1 &1A2 substrate
    		  
    • C238 S(−)-Cyanopindolol hemifumarate salt solid, ≥98% (HPLC) 5-HT1A/1B serotonin receptor antagonist; β3-adrenoceptor antagonist.
    		  
    • 28605 3-Cyanoumbelliferone BioReagent, suitable for fluorescence, ≥98.0% (TLC)   human ... MIF(4282)
    • C6493 Cyclapolin 9 powder Cyclapolin 9 is a Polo-like kinase (Plk) inhibitor. IC50 is 500 nM; selective against a panel of 20 kinases
    		  
    • C247 Cyclazosin hydrochloride solid α1B-adrenoceptor antagonist.
    		  
    • C7344 Cyclic adenosine diphosphate-ribose ≥90% (HPLC), lyophilized powder Mobilizes intracellular Ca2+; regulates Ca2+-induced Ca2+ release specifically blocked by ryanodine; second messenger for glucose-induced insulin release from endocrine pancreas and for abscisic acid-induced calcium release in plants.
    		  
    • D7939 Cyclic 3-deaza-adenosine diphosphate-ribose ~95% (HPLC), oil Heat and hydrolysis resistant cyclic ADP ribose agonist.
    		  
    • P4236 Cyclic Pifithrin-α hydrobromide ≥98% (HPLC) A stable analog of Pifithrin-α (Product Code P4359) with similar biological activities and lower cellular toxicity.
    		  
    • C4801 Cyclo(7-aminoheptanoyl-Phe-D-Trp-Lys-Thr[Bzl]) ≥95% (HPLC), powder Somatostatin antagonist.
    		 human ... SST(6750)
    mouse ... SST(20604)
    rat ... SST(24797)
    • C4542 Cyclobenzaprine hydrochloride Skeletal muscle relaxant; reduces muscle spasm by depression of brainstem neurons; 5-HT2 serotonin receptor antagonist.
    		 human ... HTR2A(3356), HTR2B(3357), HTR2C(3358)
    • C3490 Cyclofenil ≥98% (HPLC), white solid Cyclofenil is a selective estrogen receptor β antagonist.
    		  
    • C101400 1,2-Cyclohexanedione 97%   human ... ACHE(43), BCHE(590), CES1(1066)
    • 29059 1,3-Cyclohexanedione purum, for fluorescence, ≥97.0% (T)   human ... ACHE(43), BCHE(590), CES1(1066)
    • C101605 1,3-Cyclohexanedione 97%   human ... ACHE(43), BCHE(590), CES1(1066)
    • 01810 Cycloheximide ≥93.0% (HPLC) Cycloheximide (CHX) is an antibiotic produced by S. griseus. Its main biological activity is translation inhibition in eukaryotes resulting in cell growth arrest and cell death. CHX is widely used for selection of CHX-resistant strains of yeast and fungi, controlled inhibition of protein synthesis for detection of short-lived proteins and super-induction of protein expression, and apoptosis induction or facilitation of apoptosis induction by death receptors.
    		 human ... FKBP1A(2280), PIN1(5300)
    • C7698 Cycloheximide from microbial, ≥94% (TLC) Cycloheximide (CHX) is an antibiotic produced by S. griseus. Its main biological activity is translation inhibition in eukaryotes resulting in cell growth arrest and cell death. CHX is widely used for selection of CHX-resistant strains of yeast and fungi, controlled inhibition of protein synthesis for detection of short-lived proteins and super-induction of protein expression, and apoptosis induction or facilitation of apoptosis induction by death receptors.
    		 human ... FKBP1A(2280), PIN1(5300)
    • 46401 Cycloheximide PESTANAL®, analytical standard Cycloheximide (CHX) is an antibiotic produced by S. griseus. Its main biological activity is translation inhibition in eukaryotes resulting in cell growth arrest and cell death. CHX is widely used for selection of CHX-resistant strains of yeast and fungi, controlled inhibition of protein synthesis for detection of short-lived proteins and super-induction of protein expression, and apoptosis induction or facilitation of apoptosis induction by death receptors.
    		 human ... FKBP1A(2280), PIN1(5300)
    • C1988 Cycloheximide Biotechnology Performance Certified Cycloheximide (CHX) is an antibiotic produced by S. griseus that inhibits protein biosynthesis in eukaryotes. Its main biological activity is translation inhibition which results in cell growth arrest and cell death.
    Cycloheximide (CHX) is an antibiotic produced by S. griseus. Its main biological activity is translation inhibition in eukaryotes resulting in cell growth arrest and cell death. CHX is widely used for selection of CHX-resistant strains of yeast and fungi, controlled inhibition of protein synthesis for detection of short-lived proteins and super-induction of protein expression, and apoptosis induction or facilitation of apoptosis induction by death receptors.
    		 human ... FKBP1A(2280), PIN1(5300)
    • 18079 Cycloheximide solution 0.1%, for microbiology   human ... FKBP1A(2280), PIN1(5300)
    • C4859 Cycloheximide solution Ready-Made Solution, microbial, 100 mg/mL in DMSO, 0.2 μm filtered Cycloheximide (CHX) is an antibiotic produced by S. griseus. Its main biological activity is translation inhibition in eukaryotes resulting in cell growth arrest and cell death. CHX is widely used for selection of CHX-resistant strains of yeast and fungi, controlled inhibition of protein synthesis for detection of short-lived proteins and super-induction of protein expression, and apoptosis induction or facilitation of apoptosis induction by death receptors.
    		 human ... FKBP1A(2280), PIN1(5300)
    • C9901 N6-Cyclohexyladenosine Selective A1 adenosine receptor agonist.
    		 human ... ADORA1(134)
    rat ... Adora1(29290), Adora2a(25369), Adora3(25370)
    • 120685 N-Cyclohexylformamide 99%   human ... ADH1A(124), ADH1B(125), ADH1C(126), ADH4(127), ADH7(131), EPHX2(2053)
    mouse ... Ephx2(13850)
    • C106607 1-Cyclohexyl-3-(2-morpholinoethyl)-2-thiourea 97%   human ... EPHX2(2053)
    mouse ... Ephx2(13850)
    • 75475 1-Cyclohexylpiperazine ≥97.0% (GC)   mouse ... Htr3a(15561)
    rat ... Drd2(24318), Htr1a(24473)
    • C4116 Cyclopamine hydrate ≥98% (HPLC) Cyclopamine is a Hedgehog signaling pathway inhibitor; inhibits the growth of medulloblastoma cells.
    		 human ... EBP(10682)
    • C4479 9-Cyclopentyladenine monomethanesulfonate ≥98% (HPLC), solid A stable, cell-permeable, non-competitive adenylyl cyclase inhibitor that targets the P-site domain. IC50 = 100 μM in detergent-dispersed rat brain preparation.
    		  
    • C8031 N6-Cyclopentyladenosine solid Selective A1 adenosine receptor agonist.
    		 human ... ADORA1(134), ADORA2A(135), ADORA3(140)
    mouse ... Adora1(11539)
    rat ... Adora1(29290), Adora2a(25369), Adora3(25370)
    • C102 8-Cyclopentyl-1,3-dimethylxanthine ≥98% (HPLC), powder Selective A1 adenosine receptor antagonist.
    		 human ... ADORA1(134)
    • C101 8-Cyclopentyl-1,3-dipropylxanthine solid Selective A1 adenosine receptor antagonist.
    		 human ... ADORA1(134), ADORA2A(135), ADORA2B(136), ADORA3(140)
    rat ... Adora1(29290), Adora2a(25369), Adora2b(29316), Adora3(25370)
    • 246867 2-Cyclopentylphenol technical grade, 95%   human ... GABRA1(2554)
    • C8863 7-Cyclopentyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3‑d]pyrimidin-4-ylamine ≥98% (HPLC) Potent and selective inhibitor of lck, a src family tyrosine kinase.
    		 human ... KDR(3791), LCK(3932), TEK(7010)
    • C0768 Cyclophosphamide monohydrate bulk package Cyclophosphamide is a cytotoxic nitrogen mustard derivative widely used in cancer chemotherapy. It cross-links DNA, causes strand breakage, and induces mutations. Its clinical activity is associated with a decrease in aldehyde dehydrogenase 1 (ALDH1) activity.
    		 human ... ALDH1A1(216), ALDH1B1(219)
    • C1530 Cyclopiazonic acid from Penicillium cyclopium ≥98% (HPLC), powder Inhibits the sarcoplasmic reticulum Ca2+-pump.
    		 human ... ADORA1(134), ADORA2A(135), ADORA3(140)
    mouse ... Adora1(11539)
    rat ... Adora1(29290), Adora2a(25369), Adora3(25370)
    • C1368 Cyclopropanecarboxylic acid {3-[4-(3-trifluoromethyl-phenylamino)-pyrimidin-2-ylamino]-phenyl}-amide ≥98% (HPLC), solid ATP-competitive Aurora A kinase inhibitor with IC50 = 42 nM
    		  
    • C6880 D-Cycloserine powder Mode of Action: Inhibits cell wall biosynthesis (D-Ala peptide bond formation). Also prevents conversion of D-Ala to L-Ala. Bacteriostatic.
    Mode of Resistance: D-Ala transport interference.
    Partial agonist at the glycine modulatory site of NMDA glutamatergic receptors; antibiotic against Gram-negative bacteria.
    		 human ... GRIN1(2902), GRIN2A(2903), GRIN2B(2904), GRIN2C(2905), GRIN2D(2906), GRIN3A(116443), GRIN3B(116444), GRINA(2907)
    mouse ... GRIN1(14810), GRIN2A(14811), GRIN2B(14812), GRIN2C(14813), GRIN2D(14814), GRIN3A(242443), GRIN3B(170483), GRINA(66168)
    rat ... GRIN1(24408), GRIN2A(24409), GRIN2B(24410), GRIN2C(24411), GRIN2D(24412), GRIN3A(191573), GRIN3B(170796), GRINA(266668)
    • C3909 D-Cycloserine synthetic Mode of Action: Inhibits cell wall biosynthesis (D-Ala peptide bond formation). Also prevents conversion of D-Ala to L-Ala. Bacteriostatic.
    Mode of Resistance: D-Ala transport interference.
    Partial agonist at the glycine modulatory site of NMDA glutamatergic receptors; antibiotic against Gram-negative bacteria.
    		 human ... GRIN1(2902), GRIN2A(2903), GRIN2B(2904), GRIN2C(2905), GRIN2D(2906), GRINA(2907)
    • C7005 DL-Cycloserine crystalline Inhibitor of alanine aminotransferase and other pyridoxal-phosphate-requiring transaminases1; blocks sphingosine biosynthesis by inhibition of ketosphinganine synthetase.
    		 human ... GPT(2875), GPT2(84706)
    • C3662 Cyclosporin A from Tolypocladium inflatum, ≥95% (HPLC), solid A fungal metabolite possessing potent immunosuppressive properties. It inhibits the T-cell receptor signal transduction pathway via the formation of cyclosporin A−cyclophilin complex that inhibits calcineurin (protein phosphatase 2B). Inhibits nitric oxide synthesis induced by interleukin 1α, lipopolysaccharides and TNFα. Can block cytochrome c release from mitochondria.
    		 human ... PPP3CA(5530), PPP3CB(5532), PPP3CC(5533), PPP3R1(5534), PPP3R2(5535)
    • C1832 Cyclosporin A from Tolypocladium inflatum, BioReagent, for molecular biology, ≥95% A fungal metabolite possessing potent immunosuppressive properties. It inhibits the T-cell receptor signal transduction pathway via the formation of cyclosporin A−cyclophilin complex that inhibits calcineurin (protein phosphatase 2B). Inhibits nitric oxide synthesis induced by interleukin 1α, lipopolysaccharides and TNFα. Can block cytochrome c release from mitochondria.
    Potent immunosuppressive agent, inhibiting primarily T lymphocytes.
    		  
    • 30024 Cyclosporin A ≥98.5% (TLC) A fungal metabolite possessing potent immunosuppressive properties. It inhibits the T-cell receptor signal transduction pathway via the formation of cyclosporin A−cyclophilin complex that inhibits calcineurin (protein phosphatase 2B). Inhibits nitric oxide synthesis induced by interleukin 1α, lipopolysaccharides and TNFα. Can block cytochrome c release from mitochondria.
    		  
    • C9847 Cyclothiazide Blocks the rapid desensitization of the AMPA glutamate receptors and markedly prolongs the decay time of the evoked excitatory post-synaptic current.
    		 human ... CA1(759), CA4(762), GRIA1(2890), GRIA2(2891), GRIA3(2892), GRIA4(2893)
    rat ... Gria1(50592)
    • C2237 Cypermethrin ≥98% (HPLC) Type II pyrethrin. A potent inhibitor of calcineurin (protein phosphatase 2B).
    		  
    • C5493 CyPPA ≥98% (HPLC), solid CyPPA is a positive modulator of small conductance Ca2+-activated K+ channels; selective for SK3 and SK2. CyPPA is a first subtype selective SK channel positive modulator with an EC50 of 5.6 μM and 14 μM, efficacy 90% and 71% for hSK3 and hSK2, respectively. CyPPA is a tool for distinguishing SK2 and SK3 from SK1 and IK; no other agents distinguish these channels.
    		  
    • C6022 Cyproheptadine hydrochloride sesquihydrate ≥98% (TLC), solid 5-HT2/5-HT1C serotonin receptor antagonist; H1 histamine receptor antagonist; antipruritic.
    		 human ... HRH1(3269), HTR2A(3356), HTR2B(3357), HTR2C(3358)
    • C3412 Cyproterone acetate ≥98% Synthetic steroid; androgen antagonist; potent inhibitor of leukocyte migration through endothethial cell monolayers. Liver tumor promoter in experimental animal model.1 Liver tumor promotion appears to be female gender-specific, as formation of an active metabolite that forms DNA adducts.2
    		 human ... AR(367)
    mouse ... Nr3c1(14815)
    rat ... Ar(24208)
    • C3633 Cystathionine ≥90% (HPLC) Cystathionine is an intermediate in the biosynthesis of the amino acid cysteine. Cystathionine is used as a substrate to differentiate and analyze cystathionine gamma-lyase(s).
    		 human ... BHMT(635)
    • C0408   Cystatin from chicken egg white buffered aqueous glycerol solution    
    • C8917   Cystatin from chicken egg white lyophilized powder    
    • C8005 D-Cysteine hydrochloride monohydrate ≥98% (TLC)   human ... NARG2(79664)
    mouse ... NARG2(93697)
    rat ... LOC686240(686240), NARG2(691379)
    • C1276 L-Cysteine hydrochloride anhydrous, ≥98% (TLC) NMDA glutamatergic receptor agonist that is also an agonist at AMPA glutamatergic receptors at high concentrations.
    		 human ... AMPA 1(2890), GRIA2(2891), GRIA3(2892), GRIA4(2893), GRIN1(2902), GRIN2A(2903), GRIN2B(2904), GRIN2C(2905), GRIN2D(2906), GRIN3A(116443), GRIN3B(116444), GRINA(2907)
    mouse ... AMPA 1(14799), GRIA2(14800), GRIA3(53623), GRIA4(14802), GRIN1(14810), GRIN2A(14811), GRIN2B(14812), GRIN2C(14813), GRIN2D(14814), GRIN3A(242443), GRIN3B(170483), GRINA(66168)
    rat ... AMPA 1(50592), GRIA2(29627), GRIA3(29628), GRIA4(29629), GRIN1(24408), GRIN2A(24409), GRIN2B(24410), GRIN2C(24411), GRIN2D(24412), GRIN3A(191573), GRIN3B(170796), GRINA(266668)
    • C7477 L-Cysteine hydrochloride anhydrous, from non-animal source, BioReagent, suitable for cell culture, ≥98.0% NMDA glutamatergic receptor agonist that is also an agonist at AMPA glutamatergic receptors at high concentrations.
    		  
    • 30120 L-Cysteine hydrochloride anhydrous, ≥99.0% (RT) NMDA glutamatergic receptor agonist that is also an agonist at AMPA glutamatergic receptors at high concentrations.
    		  
    • C7880 L-Cysteine hydrochloride monohydrate reagent grade, ≥98% (TLC) NMDA glutamatergic receptor antagonist.
    		  
    • C6852 L-Cysteine hydrochloride monohydrate from non-animal source, cell culture tested, meets EP, USP testing specifications NMDA glutamatergic receptor antagonist.
    		  
    • C5610 L-Cysteine hydrochloride monohydrate PharmaGrade, Ajinomoto, EP, USP, manufactured under appropriate GMP controls for Pharma or Biopharmaceutical production, suitable for cell culture NMDA glutamatergic receptor antagonist.
    		  
    • 30122 L-Cysteine hydrochloride monohydrate Ph Eur NMDA glutamatergic receptor antagonist.
    		  
    • 30129 L-Cysteine hydrochloride monohydrate BioUltra, ≥99.0% (RT) NMDA glutamatergic receptor antagonist.
    		  
    • 30130 L-Cysteine hydrochloride monohydrate ≥99.0% (RT) NMDA glutamatergic receptor antagonist.
    		  
    • C4418 L-Cysteinesulfinic acid monohydrate Putative excitatory amino acid neurotransmitter
    		  
    • C0256 Cytidine 5′-diphosphocholine sodium salt dihydrate ~98%, from yeast, solid Neuroprotective in situations of hypoxia and ischemia; biosynthetic intermediate of membrane phospholipids; cerebral vasodilator; inhibits PLA2 activation.
    		  
    • C0985 Cytidine 3′,5′-cyclic mono­phos­phate sodium salt >98% (HPLC) Produced by the hydrolysis of cytidine 5′-triphos­phate by the enzyme cytidylyl cyclase.
    		  
    • C1506 Cytidine 5′-triphosphate disodium salt ≥95% P2X4 purinergic receptor agonist.
    		  
    • C2899 Cytisine ≥99%, powder Potent agonist at α3β4 and α7 nicotinic acetylcholine receptors and partial agonist at α4β2 nicotinic acetylcholine receptors.
    		 rat ... Chrna2(170945), Chrna3(25101), Chrna4(25590)
    • C6637 Cytochalasin A from Drechslera dematioidea Cytochalasin A reacts with sulfhydryls, and inhibits growth and glucose transport in Saccharomyces. Cytochalasin A is an oxidizing analog of cytochalsin B.
    		  
    • C2149 Cytochalasin E from Aspergillus clavatus Cytochalasin E is a cell-permeable fungal toxin that inhibits actin polymerization stimulated by F-actin. Cytochalasin E does not inhibit glucose transport.
    		  
    • C1768 Cytosine β-D-arabinofuranoside crystalline, ≥90% (HPLC) Ara-C incorporates into DNA and inhibits DNA replication by forming cleavage complexes with topoisomerase I resulting in DNA fragmentation; does not inhibit RNA synthesis. Anti-leukemia agent.
    		 human ... POLB(5423)
    mouse ... Cda(72269)
    • C6645 Cytosine β-D-arabinofuranoside hydrochloride crystalline Ara-C is phosphorylated to Ara-CTP and is incorporatee into DNA. It inhibits DNA replication by forming cleavage complexes with topoisomerase I resulting in DNA fragmentation, and ultimately induces apoptosis via the PKC signaling pathway.1 Does not inhibit RNA synthesis. Anti-leukemia agent.